Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $222.8 million.

  • Rocket Pharmaceuticals' Cash & Equivalents fell 5.47% to $222.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.8 million, marking a year-over-year decrease of 5.47%. This contributed to the annual value of $163.6 million for FY2024, which is 192.71% up from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Cash & Equivalents is $222.8 million, which was down 17.94% from $271.5 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Cash & Equivalents high stood at $466.4 million for Q1 2021, and its period low was $55.9 million during Q4 2023.
  • Its 3-year average for Cash & Equivalents is $271.0 million, with a median of $278.8 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 60.22% in 2023, then skyrocketed by 192.71% in 2024.
  • Rocket Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $232.7 million in 2021, then slumped by 39.61% to $140.5 million in 2022, then plummeted by 60.22% to $55.9 million in 2023, then spiked by 192.71% to $163.6 million in 2024, then decreased by 5.47% to $222.8 million in 2025.
  • Its Cash & Equivalents was $222.8 million in Q3 2025, compared to $271.5 million in Q2 2025 and $318.2 million in Q1 2025.